Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMP... (the first FDA-cleared diagnostic ofits k...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMPO(TM) Test

Date:11/4/2008

the first FDA-cleared diagnostic of its kind. PrognostiX' proprietary product pipeline includes valuable, high-margin cardiovascular and inflammatory biomarkers licensed to it exclusively by the Cleveland Clinic, the world's most respected cardiovascular center. Among these pipeline products is a novel biomarker that complements the cholesterol test, providing additional, more precise information for coronary artery disease risk assessment. The company also operates a CLIA-certified specialty reference laboratory, enabling it to bring promising new cardiovascular biomarkers to market more quickly. To learn more about PrognostiX, its product menu and pipeline, please visit http://www.prognostix.com.

Dr Hazen is lead investigator and a co-inventor of the Cleveland Clinic research team that discovered blood MPO levels serve as a diagnostic marker for cardiovascular disease risk and a monitor of responses to cardiac and anti-inflammatory therapies. Dr. Hazen is the scientific founder and paid consultant for PrognostiX Inc.

This press release may contain forward-looking statements within the meaning of the federal securities laws, including statements the potential benefits and impact of the CardioMPO Test. These statements reflect Inverness' current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market acceptance of the product; the ability to successfully manufacture and distribute the product; the ability to secure and maintain the regulatory approvals or clearances necessary to sell the product in various markets; and the risks and uncertainties described in Inverness' annual report on Form 10-K, and other factors identified from time to time in its periodic filings with the Securities and Exchange Commission. Inv
'/>"/>

SOURCE Inverness Medical Innovations Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

Breaking Medicine News(10 mins):Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2 Health News:University of Utah Announces New Studies on the Benefits of Treadmill Desks 2 Health News:University of Utah Announces New Studies on the Benefits of Treadmill Desks 3 Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2 Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3 Health News:Polar Pump: E85 Fuel Now Available in Warroad, Minn., Northernmost Outlet for the Fuel in USA 2 Health News:Vitamin D Linked to Survival in Lymphoma Patients 2

[0] Injury Funds Now To the Rescue with New Lawsuit Funding Service [0] University of Utah Announces New Studies on the Benefits of Treadmill Desks [1] $12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP)[0] Polar Pump: E85 Fuel Now Available in Warroad, Minn., Northernmost Outlet for the Fuel in USA [0] Vitamin D Linked to Survival in Lymphoma Patients

Abraham Lincoln Presenter to Speak in Tulsa This Saturday Midwest Meets West Coast, The Chicago School of Professional Psychology to Open New Campus in Downtown Los Angeles President Bush Declares March as Red Cross Month EMSI Introduces U-Direct for Life Insurance Direct Marketers Universal Health Services, Inc. Reports 2007 Fourth Quarter and Full Year Earnings and 2008 Guidance As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years, Technology will be Called upon to Stem the Tide

Breaking Medicine Technology:SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 2 SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 3 NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2 Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2 Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3 Varian Medical Systems Adds RapidArc 28R 29 and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clin 55663 1 Varian Medical Systems Adds RapidArc 28R 29 and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clin 55663 2 Varian Medical Systems Adds RapidArc 28R 29 and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clin 55663 3 Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 1 Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 2 Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 3 Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference 13733 4 Strategic Alliance Between Televisa and Genomma Lab 55658 1 Strategic Alliance Between Televisa and Genomma Lab 55658 2

[0] SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology [0] NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock [0] Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock

Other Medicine Technology:Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 2 Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 3 Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 4 Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 5 Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 6 Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia 7 Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 2 Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 3 Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 4 Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring 5

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring

Medicine Products:

ENDO STITCHtrade; Short 10 mm Suturing Device ENDOKNOT Suture Type - 0 Coated VICRYL ENDOLOOP Suture Type - 0 MONOCRYL ENDOLOOP Ligature Type - 0 Chromic Gut

Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMP...(the first FDA-cleared diagnostic ofits k...),Health